A patient three days out from her first Botox cycle sends a photo. Her left upper eyelid is sitting lower than the right, and she wants to know whether it is permanent, whether it means the treatment is not for her, and whether the neck ache she has had since the session is the same problem. The droop is not permanent, it does not rule out the treatment, and the neck ache is a separate effect. Every one of her questions is reasonable, and the trial data answer them better than reassurance does.
The safety record of Botox™ (onabotulinumtoxinA) in chronic migraine rests on two placebo-controlled trials, a 56-week extension, a two-year open-label study of nine rounds, and a two-year real-world study. The side effects are well counted. What is less often explained is why each one happens, which tells you whether technique can reduce it.
The numbers, and where they come from
The PREEMPT program randomized 1,384 adults with chronic migraine to onabotulinumtoxinA or placebo for two 12-week cycles, then treated everyone in an open-label extension to 56 weeks (Dodick 2010, Aurora 2011). Any adverse event occurred in 62.4% of Botox™ patients and 51.7% of placebo patients in the double-blind phase, and 3.8% versus 1.2% discontinued because of one (Dodick 2010). The FDA label’s table for those two trials (687 patients on Botox™, 692 on placebo) lists the reactions that were more frequent with treatment: neck pain (9% versus 3%), headache (5% versus 3%), migraine (4% versus 3%), eyelid ptosis (4% versus under 1%), musculoskeletal stiffness (4% versus 1%), muscular weakness (4% versus under 1%), myalgia (3% versus 1%), musculoskeletal pain (3% versus 1%), injection-site pain (3% versus 2%), bronchitis (3% versus 2%), facial paresis (2% versus 0%), muscle spasms (2% versus 1%), and hypertension (2% versus 1%) (AbbVie 2024). The same label notes that severe worsening of migraine requiring hospitalization occurred in about 1% of treated patients, usually within the first week, against 0.3% on placebo.
The pooled safety analysis of four placebo-controlled trials, two phase 2 and two phase 3, followed 1,997 patients who received at least one dose at 75 to 260 units, over up to five rounds including open-label treatment. Across that exposure it put neck pain at 12.6%, muscle weakness at 8.0%, musculoskeletal stiffness at 6.1%, and ptosis at 4.6%, and 3.4% stopped because of an adverse event. Serious adverse events of any cause occurred in 4.7% of Botox™ patients and 3.0% on placebo during the double-blind phase. Rates were higher in the phase 2 trials than in PREEMPT, and higher below 150 and above 200 units than at 150 to 200, which the authors linked to dosing, the injection map and injector experience (Diener 2014). Two longer studies matter for anyone planning years of treatment. COMPEL followed 716 patients through nine cycles over 108 weeks: 18.3% reported a treatment-emergent adverse event, neck pain the most common at 4.1%, and one patient had a serious treatment-related event, a rash (Blumenfeld 2018). REPOSE enrolled 641 patients in routine European practice and followed them for two years and 3,499 treatment sessions: 18.3% reported an adverse drug reaction, mostly mild to moderate, and 1.3% a serious one (Ahmed 2019).
The Cochrane review pooled 28 trials with 4,190 participants and put the risk of an adverse event about 30% higher with botulinum toxin than placebo — roughly 60 per 100 treated patients against 47 per 100 — on moderate-quality evidence (Herd 2018). What follows is the mechanism behind each item on the list, because the mechanism shows which ones technique can reduce.
Neck pain, stiffness, and a heavy head
This is the most common complaint and the one most tied to technique. Of the 31 sites in the PREEMPT map, 4 are in the cervical paraspinal muscles at the back of the neck and 6 are in the upper trapezius. The paraspinal injections are specified as superficial and high, close to the base of the skull, because the goal is the sensory nerve endings in the upper neck, not the postural muscles below them (Blumenfeld 2010, Blumenfeld 2017). An injection placed too deep or too low weakens the muscles that hold the head up. The patient feels it as a dull ache, stiffness, or a head that is hard to hold up at a screen by mid-afternoon. In the pooled trials, neck pain started about a week after an injection on average and lasted about three and a half weeks (Diener 2014).
The fix is at the next cycle, not the next day. The paraspinal injections can be kept shallow and at the upper edge of the neck, and the trapezius sites moved away from the muscle bulk for a patient with a slender neck. Patients who do heavy desk work are warned in advance and told to raise the monitor for the first three weeks. Injection-site soreness, which is separate, lasts a day or two and responds to ice.
Eyelid droop: why it happens and how it is avoided
Ptosis has the clearest mechanism of any of these side effects. The three forehead muscles in the protocol — frontalis, corrugator, procerus — sit a short distance above the orbit, and beneath the brow is the levator palpebrae superioris, the small muscle that lifts the upper lid. If toxin diffuses down into the levator, or a corrugator injection is placed low or angled toward the eye, the lid drops on that side (Blumenfeld 2017). It usually shows up within days of a round and fades as the effect wears off, typically over weeks. Vision is not affected beyond the heavy lid, but a droop still needs a call so it can be checked.
Prevention is placement: corrugator sites at the upper margin of the brow with the needle directed upward and away from the orbit, procerus in the midline, and the frontalis sites in the upper third of the forehead at the protocol dose, not more. A patient who had ptosis at one cycle gets a re-mapped forehead, not a discontinued treatment. When a drooping lid is bothersome in the meantime, an alpha-agonist eye drop that tightens the lid’s small accessory muscle can lift it slightly for a few hours.
A related, less-discussed effect is brow heaviness or an altered brow shape from the frontalis sites, which is cosmetic and resolves the same way. With repeated treatment, the injected forehead muscle can also look thinner, a change some patients like and some do not, and it is worth knowing before the first round.
Muscle weakness beyond the neck
Muscle weakness appeared in 4% of treated patients against under 1% on placebo in the controlled trials, by the label’s count. In chronic migraine it means weakness in the injected muscles: the trapezius sites can leave the shoulders feeling heavy when shrugging or carrying a bag, and the temporalis sites occasionally make chewing tough food tire the jaw. Facial weakness, reported in about 2%, is asymmetry of the forehead or brow from uneven frontalis effect. All of it tracks the 12-week cycle. Weakness that spreads to muscles that were not injected is a different category and is covered below.
Headache and “migraine” as side effects
The odd-looking lines on the label, headache at 5% and migraine at 4%, describe patients whose headache was recorded as an adverse event. In the pooled trials these headaches were no more severe than the ones recorded on placebo, and they began on average about three weeks after an injection, not in the first days (Diener 2014). Some of this is the underlying disease continuing while the effect builds, and some is injection-site soreness on the scalp read as headache. The label also records severe worsening of migraine requiring hospitalization in about 1% of treated patients, usually within the first week, against 0.3% on placebo, which is why a first-week flare that is unlike your usual attacks gets a phone call rather than a wait. A rough first week does not predict a failed round. Headache days kept falling across five rounds in the 56-week program (Aurora 2011), which is why the decision to continue or stop is made after two or three rounds rather than after a rough first week.
The boxed warning: distant spread of toxin effect
Every botulinum toxin product carries an FDA boxed warning: weakness, difficulty swallowing, or difficulty breathing appearing hours to weeks after injection, when the toxin acts beyond the injected area. The label says the risk is probably greatest in children treated for spasticity (AbbVie 2024). At the 155-unit chronic migraine dose, delivered as 5-unit aliquots into superficial scalp and neck muscles, the exposure per site is small. Dysphagia appears on the label’s list of migraine reactions at under 1%. The label notes that no definitive serious case of distant spread has been reported at the labeled chronic migraine dose, and a case-by-case review of the pooled trials found no adverse event due to distant spread (AbbVie 2024, Diener 2014).
Rare does not mean ignorable. If you have new trouble swallowing or breathing at any point after a session, call 911 or go to the nearest emergency room. A change in voice or weakness in muscles that were not injected needs a same-day call. The patients at higher risk are those with a neuromuscular disorder such as myasthenia gravis or ALS, pre-existing swallowing or breathing problems, or medications that act at the neuromuscular junction, including aminoglycoside antibiotics (AbbVie 2024). All of those are asked about before the first round, and a neuromuscular disorder is weighed carefully before deciding to treat.
Allergic reaction, pregnancy, and what is not known
True hypersensitivity to botulinum toxin products is rare and is a contraindication to further treatment, as is infection at any planned site. There are no adequate studies of Botox™ in pregnancy or breastfeeding (AbbVie 2024), so if you are pregnant, planning a pregnancy or breastfeeding, tell us before the next round, and it is usually deferred. The other question patients ask is about combining Botox™ with the CGRP antibodies. In a chart review of 257 patients who added a CGRP antibody to Botox™, no new safety signals appeared, though it was not a randomized trial (Blumenfeld 2021). It is a co-management conversation with neurology rather than a contraindication.
Neutralizing antibodies and the reason cycles are 12 weeks
The immune system can form antibodies that bind and inactivate the toxin, after which the injections stop working. Botulinum toxin type A products show low rates of clinically detectable antibodies, and the risk rises with higher total doses and booster injections (Naumann 2013). In the phase 2 chronic migraine trials, no tested patient had neutralizing antibodies (Diener 2014). That is one reason the interval is held at 12 weeks even when a patient’s benefit fades at week ten, and a “top-up” between rounds is declined. A patient whose response has faded across two or three well-executed rounds is reassessed, starting with the more common explanations: the diagnosis, medication overuse, or a map that needs updating.
What is done at Modal Pain Management NYC to keep the list short
The injection map follows the PREEMPT paradigm exactly, with the modifications the anatomy studies support: brow sites at the upper margin and angled away from the orbit, paraspinal sites high and superficial, trapezius sites adjusted to the patient’s build (Blumenfeld 2017). Every side effect from a previous cycle is recorded against the site that caused it and the map is changed before the next. Neuromuscular disease, swallowing or breathing problems, pregnancy, and interacting medications are screened at the consultation. Patients hear what to expect before the first session, because a heavy lid or a stiff neck that was predicted is a nuisance rather than an alarm.
If you are working out whether Botox™ is right for your headaches, the chronic migraine Botox eligibility check takes two minutes, the coverage guide explains what the authorization needs, and the full treatment guide covers the protocol from first visit to results.
References
- Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936. doi:10.1111/j.1526-4610.2010.01678.x · PubMed 20487038
- Diener HC, Dodick DW, Turkel CC, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851–859. doi:10.1111/ene.12393 · PubMed 24628923
- Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–1373. doi:10.1111/j.1526-4610.2011.01990.x · PubMed 21883197
- Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine (COMPEL): a multicenter, open-label study. J Headache Pain. 2018;19(1):13. doi:10.1186/s10194-018-0840-8 · PubMed 29404713
- Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):26. doi:10.1186/s10194-019-0976-1 · PubMed 30845917
- Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6(6):CD011616. doi:10.1002/14651858.CD011616.pub2 · PubMed 29939406
- Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–1418. doi:10.1111/j.1526-4610.2010.01766.x · PubMed 20958294
- Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766–777. doi:10.1111/head.13074 · PubMed 28387038
- Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120(2):275–290. doi:10.1007/s00702-012-0893-9 · PubMed 23008029
- Blumenfeld AM, Frishberg BM, Schim JD, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809–826. doi:10.1007/s40122-021-00264-x · PubMed 33880725
- AbbVie. BOTOX (onabotulinumtoxinA) for injection: full prescribing information and Medication Guide (Medication Guide revised 10/2024). DailyMed, U.S. National Library of Medicine. Accessed October 10, 2026. DailyMed
Frequently Asked Questions
In the two placebo-controlled PREEMPT trials (687 patients on Botox, 692 on placebo), the FDA label lists neck pain (9% versus 3%), headache (5% versus 3%), migraine (4% versus 3%), eyelid droop (4% versus under 1%), musculoskeletal stiffness (4% versus 1%) and muscle weakness (4% versus under 1%) as more frequent with Botox. Myalgia, musculoskeletal pain, injection-site pain, bronchitis, facial weakness, muscle spasms and high blood pressure each ran at 2 to 3%. Any adverse event occurred in 62.4% of Botox patients against 51.7% on placebo, and 3.8% versus 1.2% stopped because of one (Dodick 2010). Most were mild to moderate and faded as the toxin wore off.
The forehead sites of the PREEMPT map, in the frontalis, corrugator and procerus muscles, sit above the levator palpebrae superioris, the small muscle that lifts the upper eyelid. If toxin spreads down into it, or a brow injection is placed too low or angled toward the eye, the lid droops on that side (Blumenfeld 2017). In the trials it affected 4% of patients on Botox against under 1% on placebo (AbbVie 2024). It is not dangerous, and it fades as the toxin wears off, usually over weeks. A drooping lid still needs a call so we can check it. At the next round the brow sites are placed higher and angled away from the eye.
It can. Of the 31 protocol sites, 4 are in the cervical paraspinal muscles at the back of the neck and 6 in the upper trapezius. In the pooled trials, neck pain started about a week after an injection on average and lasted about three and a half weeks, and muscle weakness started about five days after and lasted about a month (Diener 2014). The paraspinal injections are meant to be high and superficial, and injecting too deep or too low weakens the muscles that hold the head up (Blumenfeld 2017). At the next round the paraspinal depth and placement can be adjusted and the trapezius sites moved within the muscle, keeping the fixed 155-unit protocol.
Sometimes. Headache was recorded as a side effect in 5% of patients on Botox and 3% on placebo in the PREEMPT trials, and migraine in 4% against 3% (AbbVie 2024). In the pooled analysis these headaches were no more severe than on placebo and started on average about three weeks after an injection, not in the first days (Diener 2014). A small number of patients have a bad early flare: severe worsening of migraine that needed hospital care occurred in about 1% of Botox patients, usually within the first week, against 0.3% on placebo. A flare unlike your usual attacks needs a call. A rough first week does not mean the treatment has failed.
Every botulinum toxin product carries an FDA boxed warning for distant spread of toxin effect: weakness, trouble swallowing or trouble breathing hours to weeks after injection. The label notes that no definitive serious case has been reported at the labeled chronic migraine dose (AbbVie 2024), and a review of the pooled trials found no adverse event due to distant spread (Diener 2014). Serious adverse events of any cause occurred in 4.7% of Botox patients and 3.0% on placebo in the double-blind trials (Diener 2014). In the two-year REPOSE study, 1.3% of patients had a serious drug reaction (Ahmed 2019). For trouble breathing or swallowing, call 911 or go to the nearest emergency room.
Over two years, no new problems have emerged. In the COMPEL study, 716 patients were offered nine rounds over 108 weeks. 18.3% reported a treatment-emergent adverse event, neck pain was the most common at 4.1%, and one patient had a serious treatment-related event, a rash (Blumenfeld 2018). In PREEMPT patients who completed five rounds, the share reporting any adverse event fell from 48% in the first round to 19% in the fifth (Diener 2014). The long-term issue worth knowing is neutralizing antibodies, which can stop the toxin working. They are uncommon with onabotulinumtoxinA, and the risk rises with higher total doses and booster injections between rounds (Naumann 2013), one reason rounds stay 12 weeks apart.


